Equity strategies

FP Carmignac European Leaders

OEICEuropean marketSRI Fund
Share Class

GB00BJHPHZ49

A high-conviction, bottom-up European Ex-UK Equity strategy
  • An investment process seeking profitable companies with attractive long-term prospects, built on robust fundamentals and strong business models
  • A high-conviction, low turnover, concentrated portfolio designed to maximise long-term alpha generation
  • A socially responsible approach which includes negative screening, ESG criteria integration, and a low carbon emission approach
Asset Allocation
Equities97.8 %
Other2.2 %
Data as of:  31 Mar 2025.
Risk Indicator

1

2

3

4

5

6

7

Lowest risk Highest risk
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
+ 67.3 %
-
+ 56.0 %
+ 13.6 %
- 5.7 %
From 15/05/2019
To 16/04/2025
Calendar Year Performance 2024
-
-
-
-
+ 18.2 %
+ 27.1 %
+ 13.9 %
- 14.8 %
+ 13.9 %
+ 6.8 %
Net Asset Value
1.67 £
Asset Under Management
94 M £
Net Equity Exposure31/03/2025
97.8 %
Data as of:  16 Apr 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

FP Carmignac European Leaders fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  31 Mar 2025.
Fund management team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager

Market environment

  • In March, European markets experienced a challenging period, with indices declining by 4%, particularly in economically sensitive sectors such as Industrials, Chemicals, Technology, and Healthcare.
  • Germany's fiscal stimulus measures, including a €500 billion infrastructure investment fund, provided substantial support to European markets.
  • However, the market narrative was dominated by tariff developments, with auto tariffs being confirmed in the last week of the month. Additionally, the market is preparing for the possibility of further tariffs from the Trump administration.
  • We expect these developments to act as a pivotal moment for the market, especially for stocks with significant international exposure and sales.

Performance commentary

  • In March, the fund registered a negative performance in both absolute and relative terms.
  • This underperformance was primarily driven by a notable shift in investor sentiment from growth stocks.
  • Our selection of stocks in the Financials sector contributed positively to the fund's performance. Notably, Deutsche Börse and Euronext demonstrated resilience to market volatility and performed well during the month.
  • However, the main detractors were stocks in the Healthcare and Information Technology sectors.
  • Novo Nordisk was the biggest detractor, as the growth rate for its obesity drug stalled, fuelling investor concerns about its sales guidance during the Q1 results.

Outlook strategy

  • During the month, we made some adjustments to our portfolio by initiating a new position in the Fund.
  • Throughout the month, we continued to enhance our exposure to Industrials by increasing our holdings in Schneider Electric but also Prysmian and Kingspan, which we recently initiated.
  • We started a small position in IMCD, a high-quality chemical distribution company that we have previously owned.
  • The stock has significantly derated in recent years due to rising bond yields, and we anticipate it will perform well in the current market environment.
  • Conversely, we reduced our positions in Euronext, Deutsche Börse, and Elis, which have performed well recently.
  • The Fund continues to rely on bottom-up fundamental analysis with a medium-long term horizon.
  • We continue to stick to our philosophy and believe that this is a great opportunity for our investors to gain access to a range of Europe’s best companies at attractive entry valuations.

Performance Overview

Data as of:  17 Apr 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 22/04/2025

FP Carmignac European Leaders Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  31 Mar 2025.
Europe100.0 %
View details

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  31 Mar 2025.
Equity Investment Weight97.8 %
Net Equity Exposure97.8 %
Number of Equity Issuers41
Active Share77.6 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Manager.
Fund Management Team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
In our approach to European equities, we focus on sustainable high-quality companies which demonstrate high levels of profitability while favoring profits reinvestment over profits distribution to grow the business for the future.
View Fund's characteristics

Related articles

European equities17 April 2025English

FP Carmignac European Leaders: Letter from the Fund Manager

3 minute(s) read
Find out more
Sun piercing through the clouds
European equities24 February 2025English

Beyond the plate - Why we favour personal care over food companies

5 minute(s) read
Find out more
Sun piercing through the clouds
European equities20 January 2025English

FP Carmignac European Leaders: Letter from the Fund Manager

4 minute(s) read
Find out more
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
​The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.